Incyte news and events in 2026
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients.
Public (INCY)Pharmaceutical Manufacturing5,001 to 10,000 employeesincyte.comLinkedIn
- Dated updates
- 72
- Last event
- Sep 29, 2026
- Open rolesSnapshot Sep 29, 2026
- 49
- Latest SEC filing
- Aug 31, 2026
Overview
Incyte by topic
110-K filing
49open roles
3deals
1executive move
Latest events
Latest Incyte events
Showing 10 of 12 events. The Signal API returns all of them.
Get them with one API call- LaunchMirum Pharmaceuticals, Incyte announce FDA approval of AtebriozIncyte, in collaboration with Mirum Pharmaceuticals, received FDA approval for its Atebrioz tablets, a treatment for fibrodysplasia ossificans progressiva in patients aged 12 and older.
- RevenueIncyte stock reports 38 percent revenue growth as shares trade at USD 123.47Incyte reported Q2 2026 revenue of USD 1.67 billion, a 38% increase year-over-year.
- EarningsA Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock OptionsIncyte reported a gross margin of 91.79% and an EPS of 1.52.
- AcquisitionIncyte expands haematology portfolio with vega acquisition.With VEGA Americas, Inc.
- AcquisitionIncyte's stars align as new CEO strikes $2B Vega takeover for blood disorder asset.$2B · With Vega Therapeutics, Inc.
- AcquisitionIncyte nears up to $2 billion deal for blood disorder biotech Star, FT reports.$2B · With Star Therapeutics, Inc.
- NewsPharmaEssentia appoints Eric Vogel as U.S. Head of Commercialization ahead of potential launch of BESREMi(R) in essential thrombocythemia.Vogel, Group Vice President of Sales and Marketing
- IntegrationIncyte partners with Edison Scientific to integrate AI across drug discovery and translational research.With Edison Scientific Inc.
- In developmentIncyte Corp stock (US45337C1027): Biopharma leader in oncology therapies.Incyte Corporation is developing novel therapies in oncology and inflammation.
- Executive hireIncyte appoints Suketu (Suky) Upadhyay as Chief Financial Officer.Suketu (Suky) Upadhyay, Chief Financial Officer
Showing 10 of 12 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Incyte with the Signal API
One POST /v1/companies/enrich call with incyte.com returns every signal type for Incyte, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Same industry
Companies related to Incyte
Incyte questions
What is the latest news on Incyte?
What is going on with Incyte?
Has Incyte announced any acquisitions?
What else does Autobound track for Incyte?
Is Incyte hiring right now?
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .